Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia.

Advances in Therapy
Hongyan ZhangYu Feng

Abstract

Post hoc analyses (two single-arm studies) were conducted to determine the impact of once-monthly injection of paliperidone palmitate on functioning in adult patients with schizophrenia in the Asia-Pacific region. Study 1 enrolled hospitalized patients with acute exacerbation of schizophrenia, and study 2 enrolled patients with recently diagnosed schizophrenia unsatisfactorily treated with oral antipsychotics. Patients received paliperidone palmitate, 150 mg eq. on day 1, 100 mg eq. on day 8, then once monthly (50-150 mg eq.) (study 1, days 36 and 64; study 2, 18 months). Functional status was evaluated by Personal and Social Performance score in both studies and employment only in study 2. In study 1, 54 of 184 patients (29.4%) with an unfavorable level of functioning at the baseline improved to a favorable level (Personal and Social Performance score greater than 70) at day 92. This improvement was significantly greater among patients with recently diagnosed schizophrenia (5 years or less) compared with patients with chronic schizophrenia (more than 5 years): 40% versus 22% (p < 0.0001). Improvements were observed in all four domains (socially useful activities, personal and social relationships, self-care, disturbing/aggress...Continue Reading

References

Mar 21, 2001·Biological Psychiatry·J LiebermanR Bilder
Jan 2, 2004·The American Journal of Psychiatry·Dennis S Charney
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Mar 4, 2006·The American Journal of Psychiatry·Robert RosenheckUNKNOWN CATIE Study Investigators Group
Oct 19, 2006·Journal of Psychopharmacology·Henry A Nasrallah, Rob Lasser
Dec 30, 2006·The Journal of Clinical Psychiatry·Stephan HeresStefan Leucht
Oct 19, 2007·Acta Psychiatrica Scandinavica·T Burns, D Patrick
Nov 21, 2007·The British Journal of Psychiatry. Supplement·Stefan Priebe
Jan 18, 2008·PharmacoEconomics·A George Awad, Lakshmi N P Voruganti
Oct 15, 2008·Current Opinion in Psychiatry·Georg Juckel, Pier Luigi Morosini
Oct 16, 2008·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Ariane K Kawata, Dennis A Revicki
Nov 26, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gahan PandinaGeorge Simpson
Feb 15, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Huafang LiNiufan Gu
Jul 19, 2011·Schizophrenia Research·Joseph VenturaKeith H Nuechterlein
Sep 12, 2012·Schizophrenia Research and Treatment·Borah KimYoung-Chul Chung
Jan 15, 2014·International Clinical Psychopharmacology·David Taylor, Olubanke Olofinjana
Dec 3, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·S HeresR Vauth
Mar 21, 2015·Neuropsychiatric Disease and Treatment·Fan ZhangSteve Ascher
Sep 26, 2015·Early Intervention in Psychiatry·Georgia L StevensJacqueline Zummo
Oct 4, 2015·Schizophrenia Research·Andreas SchreinerLudger Hargarter
Mar 15, 2016·International Clinical Psychopharmacology·Larry AlphsIbrahim Turkoz
Oct 13, 2016·The Journal of Clinical Psychiatry·Christoph U CorrellJohn M Kane
Dec 23, 2016·The Journal of Nervous and Mental Disease·Cynthia A BossieDong-Jing Fu

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01527305
NCT01051531

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here